메뉴 건너뛰기




Volumn 147, Issue 42, 2003, Pages 2044-2045

Imatinib: New oncological treatment principle;Nieuw oncologisch behandelprincipe met imatinib

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

EID: 0142090455     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (4)

References (19)
  • 1
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3    Gathmann, I.4    Baccarani, M.5    Cervantes, F.6
  • 2
    • 0142026838 scopus 로고    scopus 로고
    • Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans
    • Baars A, Pinedo HM. Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans. Ned Tijdschr Geneeskd 2003;147:2072-6.
    • (2003) Ned Tijdschr Geneeskd , vol.147 , pp. 2072-2076
    • Baars, A.1    Pinedo, H.M.2
  • 3
    • 0142122115 scopus 로고    scopus 로고
    • Enkele patiënten met een gemetastaseerde gastro-intestinale stromaceltumor: Gekeerde kansen door de introductie van imatinib
    • Gelderblom H, Verweij J. Enkele patiënten met een gemetastaseerde gastro-intestinale stromaceltumor: gekeerde kansen door de introductie van imatinib. Ned Tijdschr Geneeskd 2003;147:2041-3.
    • (2003) Ned Tijdschr Geneeskd , vol.147 , pp. 2041-2043
    • Gelderblom, H.1    Verweij, J.2
  • 4
    • 0142058816 scopus 로고    scopus 로고
    • Imatinib, een specifieke tyrosinekinaseremmer, voor de behandeling van patiënten met een gastro-intestinale stromaceltumor
    • Gelderblom H, Hogendoorn PCW, Graaf WTA van der, Verweij J. Imatinib, een specifieke tyrosinekinaseremmer, voor de behandeling van patiënten met een gastro-intestinale stromaceltumor. Ned Tijdschr Geneeskd 2003;147:2051-5.
    • (2003) Ned Tijdschr Geneeskd , vol.147 , pp. 2051-2055
    • Gelderblom, H.1    Hogendoorn, P.C.W.2    Van der Graaf, W.T.A.3    Verweij, J.4
  • 5
    • 0037186924 scopus 로고    scopus 로고
    • Imatinib mesylate - A new oral targeted therapy
    • Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
    • (2002) N Engl J Med , vol.346 , pp. 683-693
    • Savage, D.G.1    Antman, K.H.2
  • 6
    • 0037343949 scopus 로고    scopus 로고
    • Polycythemia vera responds to imatinib mesylate
    • Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003;325:149-52.
    • (2003) Am J Med Sci , vol.325 , pp. 149-152
    • Jones, C.M.1    Dickinson, T.M.2
  • 7
    • 0038717050 scopus 로고    scopus 로고
    • Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera
    • Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003:17:1186-7.
    • (2003) Leukemia , vol.17 , pp. 1186-1187
    • Silver, R.T.1
  • 9
    • 85117738579 scopus 로고    scopus 로고
    • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy
    • ter perse
    • Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood [ter perse].
    • Blood
    • Pardanani, A.1    Ketterling, R.P.2    Brockman, S.R.3    Flynn, H.C.4    Paternoster, S.F.5
  • 10
    • 0038386031 scopus 로고    scopus 로고
    • Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    • Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7.
    • (2003) Blood , vol.101 , pp. 3391-3397
    • Pardanani, A.1    Reeder, T.2    Porrata, L.F.3    Li, C.Y.4    Tazelaar, H.D.5    Baxter, E.J.6
  • 11
    • 0037087531 scopus 로고    scopus 로고
    • Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies
    • Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
    • (2002) J Clin Oncol , vol.20 , pp. 1692-1703
    • Heinrich, M.C.1    Blanke, C.D.2    Druker, B.J.3    Corless, C.L.4
  • 13
    • 0038176390 scopus 로고    scopus 로고
    • The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment
    • Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-7.
    • (2003) Clin Cancer Res , vol.9 , pp. 2092-2097
    • Zonder, J.A.1    Pemberton, P.2    Brandt, H.3    Mohamed, A.N.4    Schiffer, C.A.5
  • 14
    • 0036847703 scopus 로고    scopus 로고
    • Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571
    • McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002:8:3584-91.
    • (2002) Clin Cancer Res , vol.8 , pp. 3584-3591
    • McGary, E.C.1    Weber, K.2    Mills, L.3    Doucet, M.4    Lewis, V.5    Lev, D.C.6
  • 15
    • 0037146220 scopus 로고    scopus 로고
    • Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity
    • Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1673-1679
    • Merchant, M.S.1    Woo, C.W.2    Mackall, C.L.3    Thiele, C.J.4
  • 16
    • 0037986203 scopus 로고    scopus 로고
    • The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
    • Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:1889-96.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 1889-1896
    • Podtcheko, A.1    Ohtsuru, A.2    Tsuda, S.3    Namba, H.4    Saenko, V.5    Nakashima, M.6
  • 17
    • 0034691761 scopus 로고    scopus 로고
    • Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571
    • Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 2000;19:3521-8.
    • (2000) Oncogene , vol.19 , pp. 3521-3528
    • Wang, W.L.1    Healy, M.E.2    Sattler, M.3    Verma, S.4    Lin, J.5    Maulik, G.6
  • 18
    • 0037146228 scopus 로고    scopus 로고
    • Taking aim at Ewing's sarcoma: Is KIT a target and will imatinib work?
    • Druker BJ. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J Natl Cancer Inst 2002:94:1660-1.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1660-1661
    • Druker, B.J.1
  • 19
    • 0036790060 scopus 로고    scopus 로고
    • Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
    • Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
    • (2002) Cancer Res , vol.62 , pp. 5476-5484
    • Pietras, K.1    Rubin, K.2    Sjoblom, T.3    Buchdunger, E.4    Sjoquist, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.